This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up
by Zacks Equity Research
Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4
by Zacks Equity Research
Esperion Therapeutics (ESPR) generates no revenues in the fourth quarter. The company provides guidance for 2019.
Spectrum (SPPI) Misses Earnings Estimates in Q4, Tops Sales
by Zacks Equity Research
Spectrum Pharma (SPPI) misses bottom-line estimates in the fourth quarter but beats on revenues.
Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up
by Zacks Equity Research
Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.
Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.
Earnings Estimates Rising for Genomic Health (GHDX): Will It Gain?
by Zacks Equity Research
Genomic Health (GHDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Genomic Health (GHDX) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.
Genomic Health (GHDX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Genomic Health (GHDX) delivered earnings and revenue surprises of 6.67% and 2.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?
by Zacks Equity Research
Genomic Health (GHDX) is expected to gain from higher Oncotype DX breast cancer test revenues in Q4.
Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GHDX) Outperforming Other Medical Stocks This Year?
Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed
by Zacks Equity Research
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
Biogen Begins Improved Dosing Regimen on Tysabri in Phase III
by Zacks Equity Research
Biogen (BIIB) commences enrollment in late-stage study to evaluate an expanded interval dosing of its MS drug, Tysabri, in patients with relapsing MS.
Vertex Joins Forces With Arbor to Build Gene-Editing Therapies
by Zacks Equity Research
Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.
Is Genomic Health (GHDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GHDX) Outperforming Other Medical Stocks This Year?
Alnylam (ALNY) Surges: Stock Moves 8.7% Higher
by Zacks Equity Research
Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
As a result of continued efforts to streamline operations, Integer Holdings (ITGR) has been registering strong profits over the last couple of quarters.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now expanding considerably in the international arena.
Achillion Reports Positive Interim Data on Factor D Inhibitors
by Zacks Equity Research
Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.
Four Biotech Stocks That Popped More Than 50% in 2018
by Zacks Equity Research
The biotech sector has failed to impress the investors in 2018 which has underperformed the broader S&P 500 market. However, we provide four biotech companies which performed well in this scenario.
5 Stocks That Popped More Than 100% in 2018 Defying All Odds
by Sreyoshi Mukherjee
Five solid picks that defied the problems confronting the U.S. economy.
Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GHDX) Outperforming Other Medical Stocks This Year?
Cooper Companies (COO) Earnings Miss & Revenues Beat in Q4
by Zacks Equity Research
Cooper Companies (COO) gains from solid segmental performance in fiscal Q4.
Patterson Companies (PDCO) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Patterson Companies (PDCO) continues to gain from its Animal Health unit in fiscal Q2.
Genomic Health (GHDX) Down 18% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
HealthEquity's (HQY) impressive results in Q3 can be attributed to solid growth in HSA Members. Its bullish guidance for fiscal 2019 further raises investors' optimism on the stock.